A novel lipidomics-based approach to evaluating the risk of clinical hepatotoxicity potential of drugs in 3D human microtissues.

The importance of adsorption, distribution, metabolism excretion and toxicity (ADMET) analysis is expected to grow substantially due to recent failures in detecting severe toxicity issues of new chemical entities during preclinical/clinical development. Traditionally, safety risk assessment studies for humans have been conducted in animals during advanced preclinical or clinical phase of drug development. However, potential drug toxicity in humans now needs to be detected in the drug discovery process as soon as possible without reliance on animal studies. The 'omics', such as genomics, proteomics and metabolomics, have recently entered pharmaceutical research in both drug discovery and drug development, but at the best of our knowledge no applications in high-throughput safety risk assessment have been attempted so far. This paper reports an innovative method to anticipate adverse drug effects in an early discovery phase based on lipid fingerprints using human three-dimensional (3D) microtissues. The risk of clinical hepatotoxicity potential was evaluated for a dataset of 22 drugs belonging to five different therapeutic chemical classes and with various drug-induced liver injury effect. The treatment of microtissues with repeated doses of each drug allowed collecting lipid fingerprints for five time points (2, 4, 7, 9 and 11 days), and multivariate statistical analysis was applied to search for correlations with the hepatotoxic effect. The method allowed clustering of the drugs based on their hepatotoxic effect, and the observed lipid impairments for a number of drugs was confirmed by literature sources. Compared to traditional screening methods, here multiple interconnected variables (lipids) are measured simultaneously, providing a snapshot of the cellular status from the lipid perspective at a molecular level. Applied here to hepatotoxicity, the proposed workflow can be applied to several tissues, being tridimensional microtissues from various origins.

[1]  Kosuke Saito,et al.  Evaluation of the Potential Risk of Drugs to Induce Hepatotoxicity in Human—Relationships between Hepatic Steatosis Observed in Non-Clinical Toxicity Study and Hepatotoxicity in Humans- , 2017, International journal of molecular sciences.

[2]  Gabriele Cruciani,et al.  Modeling Phospholipidosis Induction: Reliability and Warnings , 2013, J. Chem. Inf. Model..

[3]  I. Zamora,et al.  High-throughput, computer assisted, specific MetID. A revolution for drug discovery. , 2013, Drug discovery today. Technologies.

[4]  Ze-jun Li,et al.  Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondria. , 2015, Toxicology and applied pharmacology.

[5]  A. D. Rodrigues,et al.  Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis. , 2016, Chemical research in toxicology.

[6]  E. Nissinen,et al.  Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects , 2002, Journal of Neural Transmission.

[7]  L. Benet,et al.  Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Subjects and Patients with Noninsulin‐Dependent Diabetes Mellitus , 1996, Journal of clinical pharmacology.

[8]  L. Goracci,et al.  A role for the autophagy regulator Transcription Factor EB in amiodarone-induced phospholipidosis. , 2015, Biochemical pharmacology.

[9]  Reijo Laaksonen,et al.  Lipidomics in drug discovery. , 2014, Drug discovery today.

[10]  R. Beckmann THE FATE OF BIGUANIDES IN MAN , 1968, Annals of the New York Academy of Sciences.

[11]  J. Kelm,et al.  Multi-cell type human liver microtissues for hepatotoxicity testing , 2012, Archives of Toxicology.

[12]  J. Swinnen,et al.  Lipidomics in drug development. , 2015, Drug discovery today. Technologies.

[13]  S. Gaine,et al.  Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension , 2009, European Respiratory Journal.

[14]  B. Cocks,et al.  Optimization of a single phase method for lipid extraction from milk. , 2016, Journal of chromatography. A.

[15]  S. Krähenbühl,et al.  Mechanisms of hepatocellular toxicity associated with dronedarone--a comparison to amiodarone. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  Weida Tong,et al.  DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. , 2016, Drug Discovery Today.

[17]  T. Riise,et al.  Quality of life as a predictor for change in disability in MS , 2000, Neurology.

[18]  M. Aleo,et al.  Liver safety evaluation of endothelin receptor antagonists using HepatoPac®: A single model impact assessment on hepatocellular health, function and bile acid disposition , 2019, Journal of applied toxicology : JAT.

[19]  J. Kornhuber,et al.  Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. , 2008, Journal of medicinal chemistry.

[20]  A. Leenhardt,et al.  Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. , 2009, British journal of clinical pharmacology.

[21]  Volker M Lauschke,et al.  Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. , 2016, Chemical research in toxicology.

[22]  Cynthia A Afshari,et al.  A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  K. Ishak,et al.  Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients , 1989, Hepatology.

[24]  Simon Messner,et al.  Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury , 2017, Archives of Toxicology.

[25]  S. Klieber,et al.  Identification of metabolic pathways and enzyme systems involved in the in vitro human hepatic metabolism of dronedarone, a potent new oral antiarrhythmic drug , 2014, Pharmacology research & perspectives.

[26]  Lulu Chen,et al.  Metformin and metabolic diseases: a focus on hepatic aspects , 2015, Frontiers of Medicine.

[27]  Alex Avdeef,et al.  Physicochemical Profiling (Solubility, Permeability and Charge State) , 2001 .

[28]  L. Marroquin,et al.  Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. , 2008, Toxicology and applied pharmacology.

[29]  R. McCallum,et al.  Amiodarone-induced liver toxicity. , 1988, Annals of internal medicine.

[30]  Hugh A Barton,et al.  Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[31]  A. D. Rodrigues,et al.  MOVING BEYOND BINARY PREDICTIONS OF HUMAN DRUG-INDUCED LIVER INJURY (DILI) TOWARDS CONTRASTING RELATIVE RISK POTENTIAL. , 2020, Chemical research in toxicology.

[32]  A. Brunet,et al.  Cross-Platform Comparison of Untargeted and Targeted Lipidomics Approaches on Aging Mouse Plasma , 2018, Scientific Reports.

[33]  K. He,et al.  Inhibition of MDR3 Activity in Human Hepatocytes by Drugs Associated with Liver Injury. , 2015, Chemical research in toxicology.

[34]  L. Goracci,et al.  Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach. , 2015, European journal of medicinal chemistry.

[35]  A. Sinclair,et al.  The Evolution of Glucose-Lowering Drugs for Type 2 Diabetes , 2012 .

[36]  Michelle M Wiest,et al.  A lipidomic analysis of nonalcoholic fatty liver disease , 2007, Hepatology.

[37]  K. Fujimori,et al.  Very long-chain-fatty acids enhance adipogenesis through coregulation of Elovl3 and PPARγ in 3T3-L1 cells. , 2012, American journal of physiology. Endocrinology and metabolism.

[38]  Samuel Kaski,et al.  High Density Lipoprotein Structural Changes and Drug Response in Lipidomic Profiles following the Long-Term Fenofibrate Therapy in the FIELD Substudy , 2011, PloS one.

[39]  Deborah I. Bunin,et al.  Toxicogenomics and metabolomics of pentamethylchromanol (PMCol)-induced hepatotoxicity. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[40]  K. Ekroos Lipidomics: Technologies and Applications , 2012 .

[41]  Macitentan: entry-into-humans study with a new endothelin receptor antagonist , 2011, European Journal of Clinical Pharmacology.

[42]  Gabriele Cruciani,et al.  LC/MS lipid profiling from human serum: a new method for global lipid extraction , 2014, Analytical and Bioanalytical Chemistry.

[43]  Bernard Testa,et al.  Drug Metabolism for the Perplexed Medicinal Chemist , 2009, Chemistry & biodiversity.

[44]  L. Goracci,et al.  Lipostar, a Comprehensive Platform-Neutral Cheminformatics Tool for Lipidomics. , 2017, Analytical chemistry.

[45]  N. Ruderman,et al.  The effects of troglitazone on AMPK in HepG2 cells. , 2017, Archives of biochemistry and biophysics.

[46]  Milica Radisic,et al.  Advances in organ-on-a-chip engineering , 2018, Nature Reviews Materials.

[47]  Niroshini Nirmalan,et al.  “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives , 2016, Proteomes.

[48]  R. Krauss,et al.  Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study , 2010, Metabolomics.